deltatrials
Completed PHASE1 INTERVENTIONAL 4-arm NCT02133846

Safety Study of TPI-287 to Treat CBS and PSP (TPI-287-4RT)

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential Cohort, Dose-Ranging Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TPI 287 in Patients With Primary Four Repeat Tauopathies: Corticobasal Syndrome or Progressive Supranuclear Palsy

Sponsor: CBD Solutions

Conditions Corticobasal Degeneration (CBD) Corticobasal Syndrome (CBS) Primary Four Repeat Tauopathies (4RT) Progressive Supranuclear Palsy (PSP)
Interventions Placebo TPI 287 2 mg/m2 TPI-287 20 mg/m2 TPI-287 6.3 mg/m2
Updated 7 times since 2017 Last updated: Apr 13, 2020 Started: May 31, 2014 Primary completion: Sep 30, 2019 Completion: Sep 30, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Corticobasal Degeneration (CBD) and Corticobasal Syndrome (CBS) and is currently completed. CBD Solutions leads this study, which shows 7 recorded versions since 2014 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotActive Not Recruiting~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotActive Not Recruiting~Jun 2018 – ~May 2020 · 23 months · monthly snapshotActive Not Recruiting~May 2020 – ~Jan 2021 · 8 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 22 months · monthly snapshotCompleted

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  4. May 2020 — Jan 2021 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  5. Jun 2018 — May 2020 [monthly]

    Active Not Recruiting PHASE1

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE1

  2. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE1

    First recorded

May 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • CBD Solutions
  • Tau Consortium
  • University of California, San Francisco
Data source: University of California, San Francisco

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations